| CDWEX | VEMIX | CDWEX / VEMIX | |
| Total Expense Ratio | 1.39 | 0.09 | 1,544% |
| Annual Report Gross Expense Ratio | 1.39 | 0.09 | 1,544% |
| Fund Existence | 12 years | 26 years | - |
| Gain YTD | 32.423 | 21.721 | 149% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.18B | 141B | 2% |
| Annual Yield % from dividends | 0.98 | 2.82 | 35% |
| Returns for 1 year | 30.57 | 20.22 | 151% |
| Returns for 3 years | 52.07 | 46.12 | 113% |
| Returns for 5 years | 19.09 | 20.62 | 93% |
| Returns for 10 years | 85.72 | 89.03 | 96% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IHE | 86.21 | 0.86 | +1.01% |
| iShares US Pharmaceuticals ETF | |||
| IWFL | 59.15 | 0.29 | +0.48% |
| ETRACS 2x Leveraged US Gr Fctr TR ETN | |||
| SCHF | 24.14 | 0.05 | +0.21% |
| Schwab International Equity ETF™ | |||
| FDTX | 41.24 | 0.08 | +0.19% |
| Fidelity Disruptive Technology ETF | |||
| XCNY | 27.98 | -0.05 | -0.19% |
| SPDR S&P Emerging Markets ex-China ETF | |||